Welcome to our dedicated page for Profound Med news (Ticker: PROF), a resource for investors and traders seeking the latest updates and insights on Profound Med stock.
Profound Medical Corp. develops and markets interventional MRI medical devices for incision-free tissue ablation. Its recurring news centers on TULSA-PRO® and the TULSA Procedure™, which use real-time MRI guidance, robotically controlled transurethral ultrasound and temperature feedback to ablate prostate tissue in prostate cancer and benign prostatic hyperplasia.
Company updates also cover Sonalleve®, an MRI-guided therapy used for pain palliation of bone metastases, desmoid tumors and osteoid osteoma, as well as gynecologic conditions including uterine fibroids and adenomyosis. Recurring developments include financial results, revenue guidance, payer coverage, CAPTAIN post-market clinical data, scientific-meeting presentations, treatment-site adoption milestones and investor conference updates.
Profound Medical (NASDAQ:PROF) will participate in two investor events in February 2026: the Lake Street Life-Sciences Invitational on Feb 4–5 in Scottsdale, AZ, and the BTIG 13th Annual MedTech conference on Feb 10–11 in Snowbird, UT. No webcasts will be available due to event formats.
Profound Medical (NASDAQ:PROF) announced that Mount Sinai Hospital performed its first incision-free, MRI-guided TULSA Procedure for prostate disease on Jan 15, 2026, making Mount Sinai the first health system in the New York Metro Area to offer TULSA-PRO.
The robotically controlled ultrasound system heats tissue to a kill temperature of 55–57°C with real-time MRI thermography and autonomous temperature adjustment, enabling tailored ablation with no procedural blood loss, same-day discharge, and intent to minimize urinary incontinence and erectile dysfunction versus surgery or radiation.
Mount Sinai is ranked No. 6 nationally for Urology (2025–26), and hospital clinicians plan future studies and guideline work using TULSA-PRO.
Profound (NASDAQ:PROF) reported its year-end TULSA-PRO installed base reached 78 systems as of December 31, 2025, exceeding its goal of 75 installs for 2025. The company also said its qualified sales pipeline grew to 97 new systems classified in the "Verify, Negotiate and Contracting" stages at year-end. Management linked the larger installed base to expectations of higher patient treatment rates and growth in recurring revenue tied to procedures, and noted upcoming Q4 and full-year 2025 financial results due near the end of February 2026.
Profound Medical (NASDAQ:PROF) announced that Johns Hopkins Hospital treated its first commercial (non‑clinical‑trial) prostate cancer patient using the TULSA-PRO system on Jan 6, 2026.
The milestone coincides with the opening of Johns Hopkins Medicine's new interventional MRI (iMRI) suite and underscores adoption of MRI-guided, incision‑free prostate ablation. The company notes TULSA-PRO uses robotically controlled directional ultrasound plus real‑time MRI thermography to target tissue, aiming for no procedural blood loss, no overnight stay, and reduced side effects versus surgery or radiation. The summary also cites prior participation in the TACT pivotal trial that led to FDA clearance.
Profound Medical (NASDAQ:PROF) closed a private placement on Dec 30, 2025, issuing 921,428 common shares at US$7.00 per share for aggregate gross proceeds of approximately US$6.45 million.
The issued shares carry a Canadian resale hold period of four months plus one day. The company intends to use net proceeds for sales and marketing, working capital, R&D, strategic transactions and general corporate purposes. Profound agreed to file a U.S. registration statement to register resale of the shares within four months of closing.
Profound Medical (NASDAQ:PROF) increased the size of its private placement announced Dec 19, 2025. The Offering will now raise gross proceeds of up to US$6.45 million through issuance of up to 921,428 common shares at US$7.00 per share. Closing is expected on or prior to December 30, 2025. Shares sold in the Offering will be subject to a four months plus one day hold period from closing. The company intends to use net proceeds for sales and marketing expansion, working capital, R&D, strategic transactions and general corporate purposes. No securities will be sold to U.S. purchasers and the securities will not be registered under the U.S. Securities Act.
Profound Medical (NASDAQ:PROF) closed a registered direct offering of 5,142,870 common shares at $7.00 per share for gross proceeds of approximately $36 million before fees and expenses. The offering had no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders.
The company said net proceeds will fund sales and marketing expansion, working capital, R&D, strategic transactions and general corporate purposes. Konik Capital Partners acted as exclusive placement agent. The offering was made from an effective Form S-3 shelf declared effective on Dec 4, 2025.
Profound expects to close a related private placement to Canadian purchasers on or before Dec 30, 2025, subject to approvals including conditional Toronto Stock Exchange approval; those securities will not be offered to U.S. persons.
Profound Medical (Nasdaq:PROF) announced a financing package of up to $40 million consisting of a $36 million registered direct offering (5,142,857 common shares at $7.00 per share) and a subsequent Canadian private placement of up to $4 million (571,428 common shares at $7.00 per share).
The registered direct offering is expected to close on or about December 22, 2025, subject to customary conditions; the private placement closing is expected on or prior to December 30, 2025 and is subject to Toronto Stock Exchange conditional approval and a four-month-plus-one-day hold period for those shares.
Gross proceeds to the company are expected to be approximately $36 million before placement agent fees and expenses, and net proceeds are planned for sales and marketing expansion, working capital, R&D, strategic transactions and general corporate purposes.
Profound Medical (NASDAQ:PROF) highlighted RSNA recognition for perioperative data from the CAPTAIN randomized controlled trial comparing MRI-guided TULSA versus robotic radical prostatectomy, presented Dec 4, 2025.
Key points: CAPTAIN successfully recruited to target as a randomized trial; the presentation received an RSNA Cum Laude award (one of six awards, top 5% of posters); reported perioperative data show robotic RP patients take ~three weeks to recover to the same state TULSA patients reach the next day; TULSA has no blood loss and no overnight stay.
Profound Medical (NASDAQ:PROF) will launch the TULSA-AI Volume Reduction module for benign prostatic hyperplasia (BPH) at RSNA, Nov 30–Dec 4, 2025, and present new TULSA-PRO clinical data at RSNA and SUO (Dec 2–5, 2025).
The AI-powered module is described as optimizing BPH treatment workflow, reducing procedure times, and enabling multiple same-day cases with existing hardware and reimbursement codes. Company cites pilot trial success, CAPTAIN perioperative data comparing TULSA favorably to robotic prostatectomy on blood loss, length of stay, post-op pain and recovery, and projects a total available prostate-disease market of ~600,000 patients annually.